
Product Data Sheet

Product Name: BMS 433796

Cat. No.: GC31012

Chemical Properties

Cas. No. 935525-13-6

SMILES O=C(N(C)N=CC1=C2C=CC=C1)[C@H]2NC(NC([C@@H](O)C3=CC(F)=CC(F)=C3)=O)=OFormula C₁₉H₁₆F₂N₄O₄ M.Wt 402.35

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol**

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Kinase experiment:

The binding assay is performed in duplicate in an assay volume of 250 μ l consisting of 25 μ L of buffer (50 mM HEPES and 0.1% CHAPSO, pH 7.0) or 10 μ M BMS-433796 to define nonspecific binding, 25 μ L of buffer containing [³H]IN973, and 200 μ L of homogenate (200 μ g of protein). Incubation is initiated by the addition of the membrane homogenates at 25°C for 1 h. Binding reactions are terminated by filtration through Whatman GF/B filters using a cell harvester. Unbound radioactivity is removed by rinsing the filters with ice-cold wash buffer (PBS; pH 7.0). Filters are counted using a 2500TR liquid scintillation counter. Saturation data are analyzed by the nonlinear regression analysis program LIGAND. Binding curves are best fit to a one-site model, yielding the equilibrium dissociation constant (K_d) and the maximal number of binding sites (B_{max})[2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1]. Prasad CV, et al.
Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. *Bioorg Med Chem Lett.* 2007 Jul 15;17(14):4006-11.
- [2]. Goldstein ME, et al.
Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. *J Pharmacol Exp Ther.* 2007 Oct;323(1):102-8.

Background

BMS 433796 is a γ -secretase inhibitor with A β lowering activity in a transgenic mouse model of Alzheimer's disease.

BMS-433796 cause a concentration-dependent decrease in [3H]IN973 binding, with IC50 value of 1.2 nM, very similar to the IC50 values for inhibition of A β 40 in human

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

embryonic kidney cells overexpressing the Swedish mutation of APP of 0.8 nM, respectively, and for inhibition of A β 42 of 0.4 nM, respectively[2].

BMS 433796 is characterized in pharmacokinetic studies in male Sprague-Dawley rats. Following a 10-min intravenous infusion at 2.3 μ mol/kg in PEG-400, the total body clearance of 40 is 5.2 ± 0.82 mL/min/kg (means \pm SEM; n=3), indicating low clearance. The apparent terminal elimination half-life is 4.6 ± 0.48 h. Oral administration of a PEG-400 suspension at 35 μ mol/kg shows an oral bioavailability of 31% with prolonged absorption. BMS 433796 has satisfactory metabolic stability in human liver microsomal preparations and is not an inhibitor of human CYPs (IC₅₀ > 100 μ M)[1]. Brain A β 40 is reduced as a result of administering BMS-433796 in a dose-dependent manner, with ED₅₀ value of 2.4 mg/kg, respectively[2].

[1]. Prasad CV, et al. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. *Bioorg Med Chem Lett*. 2007 Jul 15;17(14):4006-11. [2]. Goldstein ME, et al. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. *J Pharmacol Exp Ther*. 2007 Oct;323(1):102-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA